Abstract
Patients with biopsy-proven skin cancers require definitive treatment. As a result of healing, the temporal delay between the time of biopsy and treatment, and lack of standardized information sharing if the patient is referred to another provider, there is a risk that the biopsy site may be incorrectly identified. Other challenges include multiple lesions in an anatomic area, location in a place not visible to the patient, and proximity to other scars. In 1 study of 150 dermatologists who self-reported medical errors, wrong-site surgery was the most common “serious error.”1 In another study of 333 consecutive patients undergoing Mohs surgery, 9% were unable to identify their biopsy site.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
